Introduction
Breast cancer is one of the most common cancers among women globally. Traditional treatments like surgery, chemotherapy, and radiation remain standard, but advancements in breast cancer immunotherapy and targeted therapy have revolutionized patient outcomes. These personalized therapies focus on attacking cancer cells more precisely, sparing healthy tissues, and improving survival rates.
About Disease
Breast cancer starts in breast tissue, most often the ducts or lobules. Breast cancer can metastasize to lymph nodes and other areas if not treated. Breast cancer has a variety of subtypes, including hormone receptor-positive (HR+), HER2-positive, and triple-negative breast cancer (TNBC). Each subtype of breast cancer reacts differently to treatment, so targeted and immunotherapy are paramount in contemporary oncology.
Indications
Immunotherapy and targeted therapy are usually recommended for:
-
HER2-positive breast cancer
-
Triple-negative breast cancer (TNBC)
-
Metastatic or recurrent breast cancer
-
Patients who do not respond well to chemotherapy
-
Those eligible for biomarker-driven therapy
Testing for hormone receptors and genetic markers is essential before starting these therapies.
Treatment Details
Immunotherapy works by activating the patient’s immune system to attack cancer cells. Common agents include immune checkpoint inhibitors like PD-1 and PD-L1 inhibitors.
Targeted therapy involves drugs that specifically target molecular changes in cancer cells. For instance, HER2-positive cancers benefit from drugs that block the HER2 receptor. These treatments are often given alongside chemotherapy or hormone therapy, either orally or via IV infusion.
In India and China, such therapies are available at leading cancer centers. Hospitals like Tata Memorial Hospital (Mumbai), AIIMS (Delhi), Fudan Cancer Hospital (Shanghai), and Beijing Cancer Hospital offer these treatments under international protocols.
Medicines Used
Here are the key drugs used in breast cancer immunotherapy and targeted therapy:
Immunotherapy:
-
Atezolizumab (Tecentriq)
-
Pembrolizumab (Keytruda)
-
Durvalumab
Targeted Therapy:
-
Trastuzumab (Herceptin)
-
Pertuzumab (Perjeta)
-
Lapatinib (Tykerb)
-
Neratinib
-
Olaparib and Talazoparib (for BRCA mutations)
-
Palbociclib, Ribociclib, Abemaciclib (CDK4/6 inhibitors)
Effectiveness
The effectiveness depends on cancer subtype and genetic makeup. Immunotherapy has shown remarkable results in PD-L1 positive TNBC patients. Targeted therapy in HER2+ breast cancer has significantly improved progression-free and overall survival. For instance, Trastuzumab combined with chemotherapy has transformed HER2+ breast cancer into a treatable chronic condition.
Risks and Side Effects
While more precise than chemotherapy, these therapies do carry risks:
Immunotherapy Side Effects:
-
Fatigue
-
Inflammation of organs (lungs, liver)
-
Skin rashes
-
Hormonal imbalances
Targeted Therapy Side Effects:
-
Diarrhea
-
Heart problems (especially with HER2 inhibitors)
-
Fatigue
-
Low blood counts
Close monitoring is crucial during treatment.
Recovery and Aftercare
Recovery from immunotherapy or targeted therapy varies. Some patients continue treatment for months or years depending on response. Aftercare includes:
-
Regular blood tests and imaging
-
Cardiac monitoring (especially with HER2-targeting drugs)
-
Diet and lifestyle modifications
-
Mental health support
In India and China, follow-up care is cost-effective and available in both government and private hospitals.
Cost and Availability
The cost of breast cancer immunotherapy and targeted therapy depends on drug type, treatment cycles, and country of treatment. India offers subsidized or generic versions of many targeted therapies. China has national insurance support for some therapies.
Patient Experiences
Patients report better tolerance of these therapies compared to traditional chemotherapy. Those with HER2+ and TNBC cancers have shown prolonged remissions. Indian and Chinese patients have benefited from access to affordable biosimilars and localized immunotherapy programs. Emotional well-being and quality of life generally improve due to fewer systemic side effects.
Cost in Countries like China, India, Israel, Malaysia, Korea, Thailand, Turkey, and USA
| Country | Trastuzumab (Herceptin) / Cycle | Immunotherapy (Atezolizumab / Cycle) | Avg Monthly Targeted Therapy | Notes |
|---|---|---|---|---|
| India | $500–$800 | $1,500–$2,200 | $1,000–$1,800 | Subsidies and biosimilars available |
| China | $800–$1,200 | $2,000–$3,000 | $1,200–$2,500 | Covered partially under state insurance |
| Israel | $1,200–$1,500 | $3,000–$4,000 | $2,500–$3,000 | Advanced clinical protocols |
| Malaysia | $1,000–$1,300 | $2,800–$3,500 | $1,500–$2,800 | Private hospitals offer international care |
| South Korea | $1,200–$1,600 | $3,000–$4,200 | $2,000–$3,500 | Tech-driven healthcare system |
| Thailand | $900–$1,200 | $2,200–$3,200 | $1,400–$2,600 | Medical tourism hub |
| Turkey | $1,000–$1,400 | $2,500–$3,800 | $1,800–$3,000 | Modern cancer centers |
| USA | $3,500–$4,800 | $6,000–$10,000 | $8,000–$12,000 | Highest costs; insurance often needed |
List of Ongoing Clinical Trials in China
-
ChiCTR2100054228 – Study of Atezolizumab + Nab-Paclitaxel in TNBC patients – Fudan University
-
NCT04891094 – Combination of Toripalimab (PD-1) with Chemotherapy in metastatic HER2+ breast cancer – Sun Yat-Sen University
-
ChiCTR2000040099 – Personalized vaccine-based immunotherapy in early-stage breast cancer – Shanghai Ruijin Hospital
-
NCT04996803 – PD-1/PD-L1 combo therapy in Chinese TNBC cohort – Peking Union Medical College
-
NCT05521675 – CDK4/6 inhibitor plus immunotherapy trial – Tianjin Medical University
These trials offer new hope and often free access to advanced therapies for eligible patients.
FAQ
Q1: Is immunotherapy better than chemotherapy for breast cancer?
A: Not always. Immunotherapy is more effective in PD-L1 positive and triple-negative cases. For others, chemotherapy may be more suitable.
Q2: How long does targeted therapy last?
A: Depending on response, targeted therapy may continue for 6 months to several years.
Q3: Can Indian patients afford these treatments?
A: Yes, especially with government schemes, generics, and treatment in public hospitals.
Q4: Is immunotherapy available in China?
A: Yes, both branded and domestic immunotherapy drugs are widely available, often covered under insurance.
Q5: What tests are needed before starting these therapies?
A: HER2 status, hormone receptor tests, BRCA mutation test, PD-L1 expression.
Q6: Are these therapies approved by regulatory authorities?
A: Yes, most of these drugs are FDA and NMPA approved and widely used globally.
Q7: Can targeted therapy cure breast cancer?
A: It significantly improves outcomes and can lead to remission, but not always a cure.
Q8: Are these therapies available in tier-2 cities in India?
A: Increasingly, yes—many private hospitals and oncology centers are expanding to smaller cities.